David Quek

Learning objectives

• Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
• Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
• Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
• Assess the interrelationships linking diabetes, HF and CVD.
• Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
• Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.